Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Decipher’s tissue-based gene expression tests for prostate and bladder cancers are widely validated and used by over 3,200 urologists/radiation oncologists at all NCCN centers in the US. Their tests provide actionable prognostic information that helps guide therapy decisions. The products have Medicare coverage across nine clinical indications for prostate cancer. Numerous studies presented at major conferences demonstrate their clinical utility in risk stratification and treatment planning for urologic cancers. The company was acquired by Veracyte in February 2021. No drug development pipeline.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Decipher Biosciences.